Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAPKeeper 301: atebimetinib plus modified gemcitabine + nab-paclitaxel versus standard gemcitabine + nab-paclitaxel in metastatic pancreatic ductal adenocarcinoma
2026-525617-31-00Phase 3Authorised
- Sponsor
- Immuneering Corporation
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of atebimetinib in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Immuneering Corporation. Primary endpoint: Overall survival. Planned start Oct 2026; status: authorised.
02
Drugs
atebimetinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2026-525617-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525617-31-00.